Zevra Therapeutics (ZVRA) Income from Continuing Operations (2014 - 2026)
Zevra Therapeutics (ZVRA) reported Income from Continuing Operations of 37890000.0 for Q1 2026, up 1322.65% on a YoY basis from 2663334.92 in Q1 2025, and up 211.47% quarter-over-quarter from 12165000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Income from Continuing Operations (2014 - 2026) Analysis & Trends
Zevra Therapeutics has reported Income from Continuing Operations for 13 years, with the latest figure at 37890000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations rose 1322.65% year-over-year to 37890000.0; the trailing twelve-month figure through Mar 2026 stood at 124218000.0 (up 235.04% YoY), and the FY2025 full-year result was 83229000.0, up 178.88% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 37890000.0, up from 12165000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 74707000.0 in Q2 2025, with the low at 35739000.0 in Q4 2024.
- Historically, Income from Continuing Operations has averaged 4887647.06 across 5 years, with a median of 10367000.0 in 2023.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 1223.42% — and 2026, when it jumped 1322.65%.
- Zevra Therapeutics' Income from Continuing Operations stood at 35494000.0 in 2022, then surged by 43.96% to 19892000.0 in 2023, then slumped by 79.67% to 35739000.0 in 2024, then soared by 134.04% to 12165000.0 in 2025, then jumped by 211.47% to 37890000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 37890000.0 (Q1 2026), 12165000.0 (Q4 2025), and 544000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Zevra Therapeutics | 704.96 Mn | 504.34 Mn | 34.30 Mn | 37.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 37.89 Mn |
| Dec 31, 2025 | 12.17 Mn |
| Sep 30, 2025 | -544,000.00 |
| Jun 30, 2025 | 74.71 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -35.74 Mn |
| Sep 30, 2024 | -33.23 Mn |
| Jun 30, 2024 | -19.93 Mn |
| Mar 31, 2024 | -16.62 Mn |
| Dec 31, 2023 | -19.89 Mn |
| Sep 30, 2023 | -10.37 Mn |
| Jun 30, 2023 | -2.57 Mn |
| Mar 31, 2023 | -13.22 Mn |
| Dec 31, 2022 | -35.49 Mn |
| Sep 30, 2022 | -5.67 Mn |
| Jun 30, 2022 | -21.97 Mn |
| Mar 31, 2022 | 10.48 Mn |
| Dec 31, 2021 | -2.68 Mn |
| Sep 30, 2021 | -1.76 Mn |
| Jun 30, 2021 | 6.20 Mn |